These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11917058)

  • 1. Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients.
    Borawski J; Myśliwiec M
    Nephrol Dial Transplant; 2002 Apr; 17(4):637-44. PubMed ID: 11917058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients.
    Borawski J; Pawlak K; Myśliwiec M
    Nephron; 2002 Aug; 91(4):671-81. PubMed ID: 12138272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients.
    Borawski J; Pawlak K; Naumnik B; Myśliwiec M
    Ren Fail; 2002 Nov; 24(6):825-37. PubMed ID: 12472204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response.
    Borawski J; Naumnik B; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 2001 Jul; 16(7):1442-7. PubMed ID: 11427638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble thrombomodulin is associated with viral hepatitis, blood pressure, and medications in haemodialysis patients.
    Borawski J; Naumnik B; Pawlak K; Myśliwiec M
    Nephrol Dial Transplant; 2001 Apr; 16(4):787-92. PubMed ID: 11274275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.
    Borawski J; Myśliwiec M
    Clin Appl Thromb Hemost; 2002 Jan; 8(1):77-84. PubMed ID: 11991244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin.
    Borawski J; Naumnik B; Myśliwiec M
    Kidney Int; 2003 Dec; 64(6):2229-37. PubMed ID: 14633147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High blood soluble receptor p80 for tumour necrosis factor-alpha is associated with erythropoietin resistance in haemodialysis patients.
    Kato A; Odamaki M; Takita T; Furuhashi M; Maruyama Y; Hishida A
    Nephrol Dial Transplant; 2001 Sep; 16(9):1838-44. PubMed ID: 11522867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
    Sitter T; Bergner A; Schiffl H
    Nephrol Dial Transplant; 2000 Aug; 15(8):1207-11. PubMed ID: 10910446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy.
    Borawski J; Naumnik B; Mysliwiec M
    Clin Appl Thromb Hemost; 2002 Oct; 8(4):359-67. PubMed ID: 12516686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
    Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
    Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unfractionated heparin but not enoxaparin causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study.
    Naumnik B; Pawlak K; Mys'liwiec M
    Clin Appl Thromb Hemost; 2009 Feb; 15(1):84-91. PubMed ID: 17895513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibroblast growth factor 23, hepatocyte growth factor, interleukin-6, high-sensitivity C-reactive protein and soluble urokinase plasminogen activator receptor. Inflammation markers in chronic haemodialysis patients?
    Almroth G; Lönn J; Uhlin F; Nayeri F; Brudin L; Andersson B; Hahn-Zoric M
    Scand J Immunol; 2013 Sep; 78(3):285-90. PubMed ID: 23721058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor system components in relation to erythropoietin therapy and bone metabolism in dialyzed patients and kidney transplant recipients.
    Małyszko J; Wołczyński S; Zbroch E; Brzósko S; Małyszko J; Myśliwiec M
    Nephron; 2002 Mar; 90(3):282-9. PubMed ID: 11867949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease.
    Malatino LS; Mallamaci F; Benedetto FA; Bellanuova I; Cataliotti A; Tripepi G; Zoccali C
    Am J Kidney Dis; 2000 Nov; 36(5):945-52. PubMed ID: 11054350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percentage of hypochromic red blood cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients.
    Braun J; Lindner K; Schreiber M; Heidler RA; Hörl WH
    Nephrol Dial Transplant; 1997 Jun; 12(6):1173-81. PubMed ID: 9198047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated hepatocyte growth factor levels at the beginning of high-flux hemodialysis are due to heparin administration.
    Christidou F; Bamichas G; Galaktidou G; Fragidis S; Gionanlis L; Frangia T; Bischiniotis T; Sombolos K
    Ren Fail; 2008; 30(9):861-4. PubMed ID: 18925524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Blood serum hepatocyte growth factor in children with chronic renal failure treated with CAPD and HD].
    Szprynger K; Szczepańska M; Morawiec-Knysak A; Dyduch A
    Pol Merkur Lekarski; 2000 Apr; 8(46):270-1. PubMed ID: 10897645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet.
    Allegra V; Martimbianco L; Vasile A
    Nephrol Dial Transplant; 1997 May; 12(5):924-32. PubMed ID: 9175044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum hepatocyte growth factor levels in patients with chronic renal failure.
    Sugimura K; Kim T; Goto T; Kasai S; Takemoto Y; Matsuda J; Yoshimoto M; Yamagami S; Kishimoto T
    Nephron; 1995; 70(3):324-8. PubMed ID: 7477621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.